NICE backpedals on decision to limit access to Roche's Tarceva
This article was originally published in Scrip
NICE has made a U-turn on its decision to restrict the use of Roche's Tarceva (erlotinib) in second-line non-small cell lung cancer (NSCLC).
You may also be interested in...
Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives.
A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.